Accrufer Becomes First FDA-Approved Prescription Iron Therapy for Children 10+

Key Takeaways

• FDA approves Accrufer for children 10+
• First prescription oral iron for pediatric patients
• Data exclusivity extended to 2028
• Phase III trial showed 1.1 g/dL hemoglobin rise
• Addresses tolerability issues of traditional iron salts

Summary

Shield Therapeutics announced that the FDA has approved Accrufer, its ferric maltol oral iron formulation, for children ages 10 and older, making it the first prescription oral iron therapy for this age group. The approval expands the drug’s label beyond adults, who have used it since 2019, and adds three years of data exclusivity through December 2028. Iron deficiency affects roughly 2.4 million U.S. children, with up to 40% of adolescent females at risk. In the pivotal FORTIS Phase III trial, patients saw a 1.1 g/dL average hemoglobin increase after 12 weeks.

Pulse Analysis

Iron deficiency remains a silent epidemic among U.S. youth, with an estimated 2.4 million children affected and adolescent females disproportionately vulnerable. Conventional iron supplements, typically iron salts, often cause gastrointestinal upset, leading to poor adherence and suboptimal correction of anemia. Clinicians have relied on off‑label use of adult formulations or over‑the‑counter products, both of which lack robust pediatric dosing data and can exacerbate compliance challenges in school‑aged patients.

Accrufer’s FDA clearance marks a watershed moment for pediatric hematology. The drug’s ferric maltol complex stabilizes iron with maltol, allowing it to bypass the harsh gastric environment and be absorbed more efficiently in the small intestine. In the FORTIS Phase III trial, adolescents receiving twice‑daily doses achieved a clinically meaningful 1.1 g/dL rise in hemoglobin over 12 weeks, while reporting fewer nausea and constipation events than with standard iron salts. The agency’s decision also grants Shield Therapeutics three additional years of data exclusivity, extending market protection to 2028 and complementing existing patents projected into the mid‑2030s.

From a commercial perspective, Accrufer positions Shield as a pioneer in the pediatric iron market, a segment previously dominated by generic supplements. The therapy’s prescription status may drive higher reimbursement rates and foster stronger relationships with pediatric specialists. Looking ahead, Shield’s plans for a pediatric suspension could unlock treatment for infants as young as one month, further expanding its addressable market. The approval underscores a broader industry shift toward formulation innovation that balances efficacy with tolerability, a trend likely to influence future FDA evaluations of pediatric‑focused therapeutics.